Price$155.00-0.37 (-0.23%)
01:30 PM07:45 PM
News · 26 weeks51-86%
2025-10-262026-04-19
Mix3190d
- Insider19(61%)
- Other6(19%)
- SEC Filings4(13%)
- Earnings2(6%)
Latest news
25 items- SECSEC Form DEFA14A filed by DaVita Inc.DEFA14A - DAVITA INC. (0000927066) (Filer)
- SECSEC Form DEF 14A filed by DaVita Inc.DEF 14A - DAVITA INC. (0000927066) (Filer)
- PRDaVita Inc. Schedules 1st Quarter 2026 Investor Conference CallDENVER, April 20, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Tuesday, May 5, 2026, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day.This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Tuesday, May 5, 2026 Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the co
- SECAmendment: SEC Form SCHEDULE 13G/A filed by DaVita Inc.SCHEDULE 13G/A - DAVITA INC. (0000927066) (Subject)
- PRDaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year ImprovementDisclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.DENVER, March 18, 2026 /PRNewswire/ -- DaVita today highlighted continued progress in value-based kidney care, underscoring how sustained investment in coordinated care models is translating into improved outcomes for people living with kidney disease. That progress is evident across both industry partnerships with major insurers and scaled programs sponsored by the Center for Medicare & Medicaid Innovation (CMMI).For more than two dec
- INSIDERDirector Arway Pamela M was granted 332 shares, increasing direct ownership by 1% to 26,695 units (SEC Form 4)4 - DAVITA INC. (0000927066) (Issuer)
- INSIDERDirector Desoer Barbara J was granted 332 shares (SEC Form 4)4 - DAVITA INC. (0000927066) (Issuer)
- INSIDERChief Operating Officer, DKC Maughan David Paul was granted 5,308 shares and covered exercise/tax liability with 13,107 shares, decreasing direct ownership by 6% to 114,467 units (SEC Form 4)4 - DAVITA INC. (0000927066) (Issuer)
- INSIDERDirector Yale Phyllis R was granted 332 shares, increasing direct ownership by 2% to 14,313 units (SEC Form 4)4 - DAVITA INC. (0000927066) (Issuer)
- INSIDERChief Executive Officer Rodriguez Javier was granted 20,900 shares, increasing direct ownership by 2% to 909,815 units (SEC Form 4)4 - DAVITA INC. (0000927066) (Issuer)
- INSIDERDirector Hollar Jason M. was granted 332 shares, increasing direct ownership by 6% to 6,355 units (SEC Form 4)4 - DAVITA INC. (0000927066) (Issuer)
- INSIDERDirector Pullin Dennis W was granted 332 shares, increasing direct ownership by 16% to 2,421 units (SEC Form 4)4 - DAVITA INC. (0000927066) (Issuer)
- INSIDERChief Accounting Officer Berry Christopher Michael was granted 3,649 shares, increasing direct ownership by 23% to 19,640 units (SEC Form 4)4 - DAVITA INC. (0000927066) (Issuer)
- INSIDERCFO and Treasurer Ackerman Joel was granted 5,706 shares and covered exercise/tax liability with 42,820 shares, decreasing direct ownership by 17% to 183,905 units (SEC Form 4)4 - DAVITA INC. (0000927066) (Issuer)
- INSIDERDirector Moore Gregory J. was granted 332 shares, increasing direct ownership by 5% to 7,563 units (SEC Form 4)4 - DAVITA INC. (0000927066) (Issuer)
- INSIDERChief Compliance Officer Hearty James O was granted 1,128 shares and covered exercise/tax liability with 11,578 shares, decreasing direct ownership by 22% to 38,137 units (SEC Form 4)4 - DAVITA INC. (0000927066) (Issuer)
- INSIDERDirector Schechter Adam H was granted 332 shares, increasing direct ownership by 6% to 5,442 units (SEC Form 4)4 - DAVITA INC. (0000927066) (Issuer)
- INSIDERChief Legal & Pub. Affairs Off Waters Kathleen Alyce was granted 3,185 shares and covered exercise/tax liability with 33,863 shares, decreasing direct ownership by 20% to 124,599 units (SEC Form 4)4 - DAVITA INC. (0000927066) (Issuer)
- INSIDERDirector Schoppert Wendy Lee was granted 332 shares (SEC Form 4)4 - DAVITA INC. (0000927066) (Issuer)
- PRAlebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysisAlebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1 Therapeutics, a newly launched company backed by leading global kidney care providers and life sciences strategic and venture capital investorsThe collaboration includes potential milestone payments of up to low triple-digit millions of U.S. dollars and tiered royalties in the low double-digit percentage range based on net sales of AP306 in the licensed territoryAlebund holds a substantial non-dilutive equit
- PRR1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney diseaseSeries A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal CarePartnership with Alebund Pharmaceuticals to gain exclusive global development and commercial rights outside of Greater China for AP306, a differentiated pan phosphate transporter inhibitor, the only agent blocking the active transport of phosphate Advancing Phase 2b clinical development of AP306 as a monotherapy for hyperphosphatemia in patients with chronic kidney disease on dialysis REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- R1 Therapeutics, Inc ("R1"), a clinical-stage biopharmaceutical company focused on the development of first-in-class thera
- INSIDERCFO and Treasurer Ackerman Joel was granted 72,582 shares, increasing direct ownership by 49% to 221,019 units (SEC Form 4)4 - DAVITA INC. (0000927066) (Issuer)
- INSIDERChief Compliance Officer Hearty James O was granted 22,289 shares, increasing direct ownership by 85% to 48,587 units (SEC Form 4)4 - DAVITA INC. (0000927066) (Issuer)
- INSIDERChief Legal & Pub. Affairs Off Waters Kathleen Alyce was granted 56,159 shares, increasing direct ownership by 57% to 155,277 units (SEC Form 4)4 - DAVITA INC. (0000927066) (Issuer)
- PRDaVita Inc. to Participate in TD Cowen's 46th Annual Health Care ConferenceDENVER, Feb. 24, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at TD Cowen's 46th Annual Health Care Conference on Monday, March 2, 2026 at 11:50 am EST.To view the live webcast, visit the TD Cowen page here and create a free registration.About DaVita Inc.DaVita (NYSE:DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 25 years. DaVita c